Regulus Therapeutics (RGLS) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a report published on Thursday morning. Zacks Investment Research currently has $1.25 target price on the biopharmaceutical company’s stock.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Several other equities research analysts also recently weighed in on RGLS. Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. Wedbush reaffirmed an outperform rating and set a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $2.46.

Shares of Regulus Therapeutics (NASDAQ RGLS) traded down $0.07 during midday trading on Thursday, hitting $1.17. The company had a trading volume of 583,800 shares, compared to its average volume of 947,220. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $2.60. The firm has a market capitalization of $128.90, a P/E ratio of -0.87 and a beta of 1.55.

A number of large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP raised its position in Regulus Therapeutics by 44.8% in the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 63,100 shares in the last quarter. South Dakota Investment Council raised its position in Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Regulus Therapeutics in the third quarter worth $750,000. NEA Management Company LLC purchased a new position in Regulus Therapeutics in the third quarter worth $13,737,000. Finally, Victory Capital Management Inc. purchased a new position in Regulus Therapeutics in the third quarter worth $347,000. Hedge funds and other institutional investors own 59.39% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://weekherald.com/2018/01/08/regulus-therapeutics-rgls-upgraded-to-buy-by-zacks-investment-research.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply